Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The shares of Zomedica Corp. (NYSE American: ZOM) fell over 10% pre-market. This is why it happened.

Zomedica Shares Fell Over 10% Pre-Market: Why It Happened

TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales

Zomedica Announces Second Quarter 2021 Financial Results

ZOM stock is trading at a discount, which means this is the perfect time for investors to trade this one for short-term profits. The post Zomedica Is an Excellent Spec Play After Falling appeared first on InvestorPlace.

Zomedica Is an Excellent Spec Play After Falling

Bed Bath & Beyond

Corsair Gaming

Express

EZGO Technologies

Cenntro Electric Group

Wish

Meme stocks are often chastised for being volatile and high risk. But there are many companies here with solid growth stories and outlooks.

The 7 Newest Meme Stocks Grabbing Retail Investor Attention

Zomedica speculators are being told to be patient, but there's a time cost to money and some will likely let ZOM stock go soon. The post Time Is Passing Too Slowly For Zomedica Speculators appeared first on InvestorPlace.

Time Is Passing Too Slowly For Zomedica Speculators

Zomedica has become a slow-motion train wreck. ZOM stock investors should look for alternatives to the animal diagnostics firm.

There's Little That's Attractive About Once-Hot Zomedica Stock… for Now

ANN ARBOR, Mich., July 30, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2021 Annual Virtual-Only Meeting of Shareholders (the “Meeting”) held on July 30, 2021.

Zomedica Announces 2021 Annual Meeting Results

While the U.S. pet market is theoretically conducive for ZOM stock, you should consider the fine print before jumping onboard. The post Zomedica Stock Might Not Appeal To Millennials as Much as Some Hope appeared first on InvestorPlace.

Zomedica Stock Might Not Appeal To Millennials as Much as Some Hope

Resignation of Zomedica's President and CMO, and the CEO are red flags. Wait to buy ZOM stock until 30 cents for a margin of safety.

Avoid Zomedica Stock As It's Bogged Down By Too Many Red Flags

Zomedica came public too soon, but it does have enough cash to see a finish line. The question is, can ZOM stock investors afford to wait?

Zomedica Is Still Working Out How to Sell Truforma. Can Investors Afford to Wait?

ZOM stock has come under price pressure recently, but the outlook is bright as Zomedica plots a road map to success. The post Ignore Zomedica's Recent Struggles.

Ignore Zomedica's Recent Struggles. The Road Ahead Remains Bright.

Two of the assays used by Zomedica's Truforma platform aren't yet available. That continues to put downward pressure on ZOM stock.

Speculative Investors Are Crazy Not to Buy Zomedica at Its Current Prices

It's not there yet, but if ZOM stock pulls back another 50% or so, the risk/return proposition will be more in your favor. The post Wait for Zomedica to Give Up More of its Meme Stock Gains appeared first on InvestorPlace.

Wait for Zomedica to Give Up More of its Meme Stock Gains

ZOM stock is rife with massive potential. But it's the same potential that has gone unfulfilled for the past few months.

Zomedica Stock Still Has a Rocky Few Months Left Ahead of It

CYREN

Evofem Biosciences Inc

Great Panther Silver

Gold Standard Ventures

Gran Tierra Energy

Oragenics

These penny stocks are trading at cheap valuations, but they also have the potential to make major waves this year. The post 7 Penny Stocks You Can Pick Up for Less Than a Dollar appeared first on InvestorPlace.

7 Penny Stocks You Can Pick Up for Less Than a Dollar

ZOM stock is trading below $1 as investors are in a holding pattern as they wait for the company to report earnings in August. The post A Little Patience Could Go a Long Way For ZOM Stock appeared first on InvestorPlace.

A Little Patience Could Go a Long Way For ZOM Stock

Adomani

Kosmos Energy

Oxbridge Re Holdings Limited

Waitr Holdings Inc

Are these industry-leading penny stocks worth watching right now? The post 7 Industry Leading Penny Stocks To Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Industry Leading Penny Stocks To Watch in July 2021

Ashford Hospitality Trust

1847 GOEDEKER INC.

Inpixon

Inuvo

Luokung Technology Corp

Cinedigm

Professional Diversity Network

Are these hot penny stocks on your watchlist this week? The post 9 Hot Penny Stocks to Watch For the Upcoming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

9 Hot Penny Stocks to Watch For the Upcoming Week

Camber Energy

Hut 8 Mining Corp

Ideanomics Inc

Iterum Therapeutics Plc

Which Reddit penny stocks are investors watching right now? Check these 7 out The post Trending Reddit Penny Stocks to Buy Now?

Trending Reddit Penny Stocks to Buy Now? Take a Look At These 7

Some stocks you can buy and forget. With Zomedica and ContextLogic, you'll want to keep a much closer eye on matters.

2 Risky Meme Stocks You Don't Want to Hold With 'Diamond Hands'

Ambev

Auddia

Tellurian

Tonix Pharmaceuticals Hld

Exela Technologies

Making a penny stocks watchlist for July? Check these 8 out The post Penny Stocks To Buy in 2021?

Penny Stocks To Buy in 2021? Check These 8 Out Next Month

InvestorPlace's Mark Hake estimates Zomedica is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy.

Zomedica Is Way Undervalued Here as Its Gear Is Catching On

Zomedica is due to report results for the current quarter on Aug. 11. Until then, investors have nothing with which to weigh ZOM stock.

Radio Silence May Indicate a Problem for Zomedica Stock

Asensus Surgical

Resonant

Diversify your portfolio with 7 high-return penny stocks that could be the next big thing based on facts instead of fantasy. The post 7 Penny Stocks That Could Be the Next Big Thing appeared first on InvestorPlace.

7 Penny Stocks That Could Be the Next Big Thing

On paper, ZOM stock seems like a no-brainer due to enthusiasm for pet ownership but dig deeper and you'll find less promising data. The post Zomedica Stock Has More Headwinds Than the Rest of the Pet Industry appeared first on InvestorPlace.

News for Zomedica Stock (ZOM)